Ted Roh: Indonesia’s Plasma Fractionation Plant Wins Social Infrastructure Deal of the Year at the IJGlobal Awards 2025
Ted Roh, President at SK Plasma Core Indonesia, shared on LinkedIn:
”Indonesia’s Plasma Fractionation Plant Recognized as Social Infrastructure Deal of the Year, APAC at IJGlobal Awards 2025
Singapore, May 2026 – Indonesia’s first plasma fractionation facility, developed through a partnership between Indonesia Investment Authority (INA) and SK Plasma through their joint venture PT SKPlasma Core Indonesia, has been recognized as Social Infrastructure Deal of the Year, APAC at the IJGlobal Awards 2025.
The award acknowledges the development of essential healthcare infrastructure addressing Indonesia’s reliance on imported Plasma Derived Medicinal Products (PDMPs), and reflects the project’s ability to bring together the necessary expertise, capital, and partnerships to support long-term healthcare development in Indonesia.
Organized by IJGlobal, the awards are presented to notable greenfield and refinancing transactions across the energy and infrastructure sectors.
Winners are selected by an independent panel of industry professionals through a structured evaluation process, with submissions assessed against criteria such as innovation, impact, and execution, and ultimately determined through a consensus-based decision.
The plasma fractionation facility, currently under development in Karawang, West Java, represents a significant step toward strengthening Indonesia’s healthcare resilience.
Once operational, the facility is expected to enable domestic processing of blood plasma into life-saving therapies such as immunoglobulin and albumin, supporting more reliable and affordable access to essential medicines.
Since the initial investment announcement in December 2024, the project has progressed through key milestones, including the introduction of plasma-derived products sourced from Indonesian donor plasma, as well as the advancement of construction for the local facility, which is targeted to commence operations by 2027.
Financing for the project has also been strengthened through a syndicated loan of IDR 3.7 trillion, led by PT Allo Bank Indonesia Tbk, alongside PT Bank Mega Tbk, supporting the continued development and readiness of the facility.”
Stay updated with Hemostasis Today.
-
May 23, 2026, 08:15Alexander Krupp: Asundexian Receives Priority Review Designation from China‘s NMPA
-
May 23, 2026, 07:59Toward a Dedicated Framework for MIg-Driven Hemostatic Disorders – JTH
-
May 23, 2026, 07:53Ankit Panthari: Can Haemophilia Serve as A Health System Model for Other Rare Diseases in India?
-
May 23, 2026, 07:36Angie Read: Stories of Strength and Resilience on The Latest Episode of Stroke Sisters
-
May 23, 2026, 07:30Ozlem Fidanci: Reflections From WHA79 on the Future of Stroke Care
-
May 23, 2026, 07:21Ney Carter Borges: Where the Benefit Appears in Dual Antiplatelet Therapy
-
May 23, 2026, 05:38SIUH Advances Precision Stroke Care with Vena MicroAngioscope – Northwell Health
-
May 23, 2026, 05:31Kalyan Roy: Precision Blood Matching in Transfusion-Dependent Thalassaemia
-
May 23, 2026, 05:29Understanding Hepatitis A, B, and C During Hepatitis Awareness Month – UNC Health